189 related articles for article (PubMed ID: 25903072)
1. Patient comorbidity is associated with conservative treatment of localized prostate cancer.
Jespersen CG; Nørgaard M; Jacobsen JB; Borre M
Scand J Urol; 2015; 49(5):366-70. PubMed ID: 25903072
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.
Abdollah F; Schmitges J; Sun M; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Int J Urol; 2012 Sep; 19(9):836-44. PubMed ID: 22574746
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
[TBL] [Abstract][Full Text] [Related]
4. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study.
Lund L; Borre M; Jacobsen J; Sørensen HT; Nørgaard M
Urology; 2008 Dec; 72(6):1258-62. PubMed ID: 18342917
[TBL] [Abstract][Full Text] [Related]
5. Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Maurice MJ; Zhu H; Kiechle JE; Kim SP; Abouassaly R
J Urol; 2016 Apr; 195(4 Pt 1):919-24. PubMed ID: 26519653
[TBL] [Abstract][Full Text] [Related]
6. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
[TBL] [Abstract][Full Text] [Related]
7. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).
Nguyen-Nielsen M; Møller H; Tjønneland A; Borre M
Cancer Epidemiol; 2020 Feb; 64():101623. PubMed ID: 31760356
[TBL] [Abstract][Full Text] [Related]
9. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
12. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
Lunardi P; Ploussard G; Grosclaude P; Roumiguié M; Soulié M; Beauval JB; Malavaud B
World J Urol; 2017 Apr; 35(4):587-593. PubMed ID: 27443847
[TBL] [Abstract][Full Text] [Related]
13. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.
Kastner C; Armitage J; Kimble A; Rawal J; Carter PG; Venn S
Prostate Cancer Prostatic Dis; 2006; 9(3):270-4. PubMed ID: 16770340
[TBL] [Abstract][Full Text] [Related]
14. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
15. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.
Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ
Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
18. Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011.
Ording AG; Horváth-Puhó E; Lash TL; Ehrenstein V; Borre M; Vyberg M; Sørensen HT
Acta Oncol; 2016 May; 55(5):611-8. PubMed ID: 26586474
[TBL] [Abstract][Full Text] [Related]
19. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation.
Sun M; Sammon JD; Becker A; Roghmann F; Tian Z; Kim SP; Larouche A; Abdollah F; Hu JC; Karakiewicz PI; Trinh QD
BJU Int; 2014 Feb; 113(2):200-8. PubMed ID: 23937636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
